Clinical trials · New Jersey
Epithelial Ovarian Cancer clinical trials in New Jersey
We’re tracking 23 recruiting epithelial ovarian cancer studies with a site in New Jersey — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New Jersey
- NCT06824467RecruitingPhase 3
Maintenance Therapy Study for Recurrent Ovarian Cancer
This study tests a new maintenance treatment (sacituzumab tirumotecan) versus standard care for people with ovarian cancer that has come back after responding to platinum-based chemotherapy. The goal is to see if it can keep the cancer from growing longer and improve quality of life.
Hackensack, New JerseyAges 18 years+ - NCT06890338RecruitingPhase 2
Carboplatin and mirvetuximab for advanced ovarian cancer
This trial tests a combination of chemotherapy (carboplatin) and a targeted drug (mirvetuximab soravtansine) given through a vein. It is for people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer that has a specific protein called folate receptor alpha (FRα) on at least 75% of tumor cells.
Hackensack, New JerseyAges 18 years+ - NCT07736937RecruitingPhase 1/Phase 2
Study of TUB-040 with Standard Drugs for Ovarian Cancer
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
East Brunswick, New JerseyAges 18 years+ - NCT06580314RecruitingPhase 3
Olaparib with or without bevacizumab for ovarian cancer
This trial tests whether taking the drug olaparib for one or two years, alone or with another drug called bevacizumab, can help keep ovarian cancer from coming back after initial chemotherapy and surgery. It is for people with certain genetic markers in their tumor.
Basking Ridge, New JerseyAges 18 years+ - NCT07059845RecruitingPhase 2
Studying mirvetuximab combos for ovarian cancer
This trial tests multiple combinations of the drug mirvetuximab soravtansine with other treatments for people with ovarian cancer. It aims to see how well these combos work and what side effects they cause.
Camden, New JerseyAges 18 years+ - NCT07218809RecruitingPhase 3
Comparison of AZD5335 vs standard treatments for advanced ovarian cancer
This trial tests a new drug, AZD5335, against standard treatments (mirvetuximab soravtansine or chemotherapy) for women with platinum-resistant ovarian cancer. It aims to see if AZD5335 works better based on the level of a protein called FRα on your tumor cells.
Camden, New JerseyAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Camden, New JerseyAges 18 years+ - NCT05659381RecruitingPhase 3
Heated belly chemo plus niraparib after interval surgery for ovarian cancer
This Phase 3 study tests whether heated chemotherapy placed inside the belly, followed by interval surgery and the maintenance medicine niraparib, can improve outcomes for certain advanced ovarian, fallopian tube, or primary peritoneal cancers. It focuses on people whose tumors are HRD/LOH positive and who can have all visible disease removed.
Teaneck, New JerseyAges 18 years+ - NCT06290193RecruitingPhase 2
Blood thinning before surgery for ovarian cancer
This trial tests if removing some blood before surgery and replacing it with fluids can reduce the need for transfusions in people with advanced ovarian cancer. It may help you have less blood loss during your operation.
Middletown, New JerseyAges 18 years+ - NCT06469281RecruitingPhase 1
A new immune cell therapy for recurring ovarian cancer
This early-phase trial tests a new immune cell therapy called 27T51, which targets a protein called MUC16 found on ovarian cancer cells. The study is for people with recurrent or treatment-resistant ovarian, primary peritoneal, or fallopian tube cancer to see if the therapy is safe and works when given alone or with other treatments.
Hackensack, New JerseyAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Hackensack, New JerseyAges 18 years+ - NCT06690775RecruitingPhase 2
Study of a new drug for platinum-resistant ovarian cancer
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
New Brunswick, New JerseyAges 18 years+ - NCT07303894RecruitingPhase 2
Isoquercetin for ovarian cancer patients
This trial tests if a plant-based supplement called isoquercetin can help people with ovarian cancer when given alongside their first chemotherapy. It aims to see if it improves treatment results.
Basking Ridge, New JerseyAges 18 years+ - NCT05429970Recruiting
Reducing stress before ovarian cancer surgery with two medicines
This study tests whether giving two commonly used medicines before surgery—one that can lower stress on the body (a beta-blocker) and one that reduces inflammation (a COX-2 inhibitor)—can improve outcomes compared with standard care. It’s for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who are having open surgery.
Middletown, New JerseyAges 18 years+ - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Hackensack, New JerseyAges 18 years+ - NCT06819007RecruitingPhase 3
Study of trastuzumab deruxtecan plus bevacizumab for HER2-positive ovarian cancer
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Paramus, New JerseyAges 18 years+ - NCT07023627RecruitingPhase 2
New pill for platinum-resistant ovarian cancer with cyclin E1
This study tests a new pill called INCB123667 for people with a type of ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if the drug can shrink tumors or slow their growth.
Hackensack, New JerseyAges 18–99 - NCT07024784RecruitingPhase 2
Study of IMGN151 for gynecologic cancers
This study tests a new drug (IMGN151) given intravenously, alone or with other therapies, for people with certain gynecologic cancers, specifically high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see how well it works and what side effects might occur.
Teaneck, New JerseyAges 18 years+ - NCT06365853RecruitingPhase 2
Study of eye safety during treatment with MIRV for recurrent ovarian cancer
This trial tests a targeted drug called mirvetuximab soravtansine (MIRV) for recurrent ovarian cancer that has high levels of a protein called FRα. The study focuses on monitoring and preventing eye-related side effects, which are common with this treatment.
Teaneck, New JerseyAges 18 years+ - NCT07546500RecruitingPhase 3
Azenosertib versus chemotherapy for advanced ovarian cancer
This trial tests a new drug called azenosertib against standard chemotherapy for ovarian, fallopian tube, or peritoneal cancer that has come back after platinum-based treatment. The drug targets a specific protein (cyclin E1) found in some tumors and may help stop cancer cells from dividing.
Camden, New JerseyAges 18 years+ - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Camden, New JerseyAges 18–60 - NCT05059444Recruiting
Blood test study to watch for cancer coming back
This study looks at whether blood tests can detect signs that cancer may return after curative-intent treatment. You would have blood drawn around your usual follow-up visits for up to 5 years, and your de-identified health data would be shared with study investigators.
East Brunswick, New JerseyAges 18 years+ - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Paramus, New JerseyAges 18 years+
Where these studies are running in New Jersey
Institutions with a site for the recruiting epithelial ovarian cancer studies listed above.
- Holy Name Medical Center · 6 studies
- John Theurer Cancer Center at Hackensack University Medical Center · 5 studies
- Rutgers Cancer Institute of New Jersey · 5 studies
- Memorial Sloan Kettering Basking Ridge · 4 studies
- Memorial Sloan Kettering Bergen · 4 studies
- Memorial Sloan Kettering Monmouth · 4 studies
- MD Anderson Cancer Center at Cooper · 3 studies
- Cooper University Health Care · 2 studies
What taking part in a epithelial ovarian cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Epithelial Ovarian Cancer trials in other states
Common questions
- Are there epithelial ovarian cancer clinical trials in New Jersey?
- Yes. We're currently tracking 23 recruiting epithelial ovarian cancer studies with a site in New Jersey, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a epithelial ovarian cancer study in New Jersey?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New Jersey to take part?
- Not necessarily. These studies have a site in New Jersey, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a epithelial ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New epithelial ovarian cancer studies open in New Jersey regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.